Daily Life Activities in Patients Treated With Continuous-Flow Left Ventricular Assist Devices

NCT ID: NCT04732039

Last Updated: 2021-02-18

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

50 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-02-08

Study Completion Date

2022-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Investigation of oxygen uptake during daily life activities in HF patients with and without LVADs.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

In patients with terminal HF the gold standard for treatment is heart transplantation, though the Worldwide shortage of donor organs has led to increased use of implantable mechanical circulatory support devices. The treatment with implantable pumps in the form of a Continuous Flow Left Ventricular Assist Device (CF-LVAD, or simply LVAD) is extremely effective for a selected patient groups leading to significant improvement in survival and quality of life.

The device is a battery-powered flow pump that carries the blood from the left ventricle to the main artery, via a cannula, and thus relieves the failing left ventricle with up to 10 liters of blood per minute. An LVAD can be used both as lifelong support therapy (Destination Therapy, DT) or until transplantation can take place (Bridge therapy).

As patients today live for more than 10 years with the device as DT, the focus has shifted from mere survival to quality of life and physical ability.

In recent years, our research group showed that the pump speed and the patient's baseline heart rhythm (sinus rhythm vs atrial fibrillation) and reduced ability to regulate the intrinsic rhythm after implantation (chronotropic incompetence) are significant contributors to the reduced exercise capacity seen in this patient group.

Until now, studies have elucidated the work capacity of this patient group using a 6-minute walk test or bicycle test - none of these reflect how well the patient actually functions in his everyday life.

In this study, we will describe oxygen uptake related to specific daily activities (ADL-VO2) and compare these with the well-known maximum work capacity (percentage of expected oxygen uptake / pVO2) in this patient group.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Left Ventricular Failure, Unspecified

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Randomized crossover study:

1. Peak oxygen uptake vs VO2 measure during specific daily life activities in LVAD recipients
2. Peak oxygen uptake vs VO2 measure during specific daily life activities in healthy controls
Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

LVAD recipients

Peak oxygen uptake vs VO2 measure during specific daily life activities in LVAD recipients

Group Type EXPERIMENTAL

Measurement of peak oxygen uptake

Intervention Type OTHER

Oxygen uptake measured on bike (pVO2) and during the conduction of specific daily life activities (ADL-VO2).

Healthy controls

Peak oxygen uptake vs VO2 measure during specific daily life activities in healthy controls.

Group Type EXPERIMENTAL

Measurement of peak oxygen uptake

Intervention Type OTHER

Oxygen uptake measured on bike (pVO2) and during the conduction of specific daily life activities (ADL-VO2).

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Measurement of peak oxygen uptake

Oxygen uptake measured on bike (pVO2) and during the conduction of specific daily life activities (ADL-VO2).

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Implanted durable left ventricular assist device
* Age\>18yrs
* Signed informed consent

Exclusion Criteria

* No consent
* Not able to complete VO2 test (physicians decision)
Minimum Eligible Age

18 Years

Maximum Eligible Age

100 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Rigshospitalet, Denmark

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Finn Gustafsson

Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Finn Gustafsson, MD,PhD,DMSci

Role: PRINCIPAL_INVESTIGATOR

Rigshospitalet, Denmark

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Rigshospitalet

Copenhagen, DK, Denmark

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Denmark

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Kiran K Mirza, MD

Role: CONTACT

+4535451442

Finn Gustafsson, MD, PhD, DMSci

Role: CONTACT

004535459743

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Kiran Mirza, MD

Role: primary

+4535451442

Finn Gustafsson, MD,PhD,DMSc.

Role: backup

+4535459743

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

H-20049568

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Pacing in Heart Failure With Preserved LVEF
NCT03215849 ENROLLING_BY_INVITATION NA